lear corporation

Discovery Laboratories (Nasdaq: DSCO) 53% LOWER; learned that the FDA will now apply a newly-defined standard to determine whether Discovery Labs has adequately demonstrated comparability of Surfaxin clinical to commercial drug product.

This new standard represents a significant hurdle for approval of Surfaxin. Lear Corporation (NYSE: LEA) 22% LOWER; NYSE Regulation has determined that the common stock of Lear Corporation (NYSE: LEA) should be suspended immediately, saying it is no longer suitable for listing on its planned Chapter 11 filing.

The maker of car seats, the Lear Corporation , said on Wednesday that it would file for bankruptcy protection in a reorganization supported by crucial secured lenders and bondholders and that it had obtained $500 million in bankruptcy financing.

Lear Corporation (NYSE: LEA) 36% LOWER; announced today that the Company has reached an agreement in principle regarding a consensual debt restructuring with steering committees representing its secured lenders and its bondholders.

The Company plans to commence shortly the proposed restructuring under court supervision pursuant to a voluntary bankruptcy filing under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its U.S. and Canadian subsidiaries.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 52.8% HIGHER; reports Q1 EPS of $0.01, 9 cents better than the analyst estimate of ($0.08) and compared to a loss of $0.79 in the same quarter last year.

Revenue for the quarter was $3.3 million, versus the consensus of $320K. Lear Corporation (NYSE: LEA) 20% LOWER; reports Q1 loss of $3.42, versus the analyst estimate of ($1.73).

Revenue for the quarter was $2.2 billion, versus the consensus of $2.15 billion. Power Medical Intervention, Inc.